Study: Acomplia Increases the Likelihood of Success in Quitting Smoking
Researchers at the University of Cincinnati Acomplia (rimonabant) College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, STRATUS-US (STudies with Rimonabant And Tobacco USe). The findings show that a new drug, rimonabant, doubled the odds of quitting smoking compared [...]
Causes of Obesity-Environmental Factors
Causes of Obesity-Environmental Factors
Along with genetics, environmental factors have been found to contribute to obesity. In particular, increased food consumptionand an inactive (sedentary) lifestyle are environmental factors that very closely correlate with an increased risk of obesity.Americans have an ever-increasing number of energydense foods, packaged in enormous portions, conveniently available at low [...]
FDA Approves New Diet Drug, But Not Acomplia or Alli (and Also Not for Humans)
For all those awaiting Food and Drug Administation action on a new diet drug, the on Jan. 5th approved one — but it was not highly anticipated Acomplia (rimonabant) and not Alli (the long-awaited over-the-counter version of Xenical).
In fact, it is not a diet drug [...]
Quitting smoking rimonabant
Quitting smoking rimonabantQuitting smoking is difficult, and the fact that quitting smoking often leads to unhealthy weight gain is often a justification for people to delay their attempts to break free from their habit.
Smoking is the leading preventable cause of death in the world today, and if [...]
Researchers Convinced Variety of Drugs Needed to Beat Body’s Stockpiling of Fat
A growing number of scientists and doctors have become convinced that overcoming the body’s imperative to stockpile fat will require an Acomplia (rimonabant) assortment of drugs, mixed and matched in various combinations, and that many patients will be taking these cocktails for years — perhaps for life — along with dieting [...]
New Studies to Test Acomplia’s Ability to Treat and Prevent Clogged Arteries
Sanofi-Aventis, the French company that is developing the promising obesity drug Acomplia (rimonabant), has disclosed that it soon intends to initiate studies aimed at determining whether Acomplia (rimonabant) can be used to treat and prevent clogged arteries and heart disease.
Dr. Douglas Greene, Sanofi-Aventis vice president for corporate and [...]
The L-Marc Research Center (Louisville Metabolic and Atheroscerosis Research Center) in Louisville, Kentucky, is one of the most active metabolic research centers in the world, focusing Acomplia (rimonabant) on Phase II-IV clinical trials of weight-loss drugs.
The clinic is a leading recruiter of participants in weight-loss trials, and [...]
Leading Doctor Cites Obesity Drugs in Attack on FDA Approval Process
A leading physician, writing in one of the world’s most influential medical journals Acomplia (rimonabant) , cited the 1990s diet drug fenfluramine and the new anti–obesity drug rimonabant in an article charging that the U.S. Food and Drug Administraton approves drugs based on “a minimal standard that would [...]
